Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Takahashi K, Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell126(4),663–676 (2006).▪▪ The landmark paper of induced pluripotent stem (iPS) cell generation from somatic cells.
  Medline CASGoogle Scholar
• 2  Okita K, Ichisaka T, Yamanaka S: Generation of germline-competent induced pluripotent stem cells. Nature448(7151),313–317 (2007).
  Medline CASGoogle Scholar
• 3  Wernig M, Meissner A, Foreman R et al.: In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature448(7151),318–324 (2007).
  Medline CASGoogle Scholar
• 4  Takahashi K, Tanabe K, Ohnuki M et al.: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell131(5),861–872 (2007).▪▪ One of the first reports on human iPS cell derivation.
  Medline CASGoogle Scholar
• 5  Yu J, Vodyanik M, Smuga-Otto K et al.: Induced pluripotent stem cell lines derived from human somatic cells. Science318(5858),1917–1920 (2007).▪▪ One of the first reports on human iPS cell derivation.
  Medline CASGoogle Scholar
• 6  Park I, Zhao R, West J et al.: Reprogramming of human somatic cells to pluripotency with defined factors. Nature451(7175),141–146 (2008).▪▪ One of the first reports on human iPS cell derivation.
  Medline CASGoogle Scholar
• 7  Lowry W, Richter L, Yachechko R et al.: Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc. Natl Acad. Sci. USA105(8),2883–2888 (2008).
  Medline CASGoogle Scholar
• 8  Mali P, Ye Z, Hommond H et al.: Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. Stem Cells26(8),1998–2005 (2008).
  Medline CASGoogle Scholar
• 9  Huangfu D, Osafune K, Maehr R et al.: Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat. Biotechnol.26(11),1269–1275 (2008).
  Medline CASGoogle Scholar
• 10  Li W, Zhou H, Abujarour R et al.: Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. Stem Cells27(12),2992–3000 (2009).
  Medline CASGoogle Scholar
• 11  Kim J, Greber B, Araúzo-Bravo M et al.: Direct reprogramming of human neural stem cells by OCT4. Nature461(7264),649–643 (2009).
  Medline CASGoogle Scholar
• 12  Giorgetti A, Montserrat N, Aasen T et al.: Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell5(4),353–357 (2009).
  Medline CASGoogle Scholar
• 13  Yu J, Hu K, Smuga-Otto K et al.: Human induced pluripotent stem cells free of vector and transgene sequences. Science324(5928),797–801 (2009).▪ The first report of virus-free and integration-free human iPS cells.
  Medline CASGoogle Scholar
• 14  Kim D, Kim C, Moon J et al.: Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell4(6),472–476 (2009).
  Medline CASGoogle Scholar
• 15  Woltjen K, Michael I, Mohseni P et al.: piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature458(7239),766–770 (2009).
  Medline CASGoogle Scholar
• 16  Yusa K, Rad R, Takeda J, Bradley A: Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat. Methods6(5),363–369 (2009).
  Medline CASGoogle Scholar
• 17  Mali P, Chou B, Yen J et al.: Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells28(4),713–720 (2010).
  Medline CASGoogle Scholar
• 18  Hanna J, Markoulaki S, Schorderet P et al.: Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell133(2),250–264 (2008).▪▪ A definitive proof on reprogramming of differentiated cell types using mouse B cells.
  Medline CASGoogle Scholar
• 19  Haase A, Olmer R, Schwanke K et al.: Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell5(4),434–441 (2009).
  Medline CASGoogle Scholar
• 20  Loh Y, Agarwal S, Park I et al.: Generation of induced pluripotent stem cells from human blood. Blood113(22),5476–5479 (2009).▪▪ The first report of human iPS cell lines generated from blood CD34+ cells after granulocyte colony-stimulating factor mobilization.
  Medline CASGoogle Scholar
• 21  Ye Z, Zhan H, Mali P et al.: Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood114(27),5473–5480 (2009).▪▪ The first demonstration of iPS cell potential for modeling aquired blood diseases.
  Medline CASGoogle Scholar
• 22  Takenaka C, Nishishita N, Takada N, Jakt L, Kawamata S: Effective generation of iPS cells from CD34⁺ cord blood cells by inhibition of p53. Exp. Hematol.38(2),154–162 (2010).
  Medline CASGoogle Scholar
• 23  Eminli S, Foudi A, Stadtfeld M et al.: Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat. Genet.41(9),968–976 (2009).▪ A comprehensive study on reprogramming potentials of different types of mouse hematopoietic cells.
  Medline CASGoogle Scholar
• 24  Hong H, Takahashi K, Ichisaka T et al.: Suppression of induced pluripotent stem cell generation by the p53–p21 pathway. Nature460(7259),1132–1135 (2009).
  Medline CASGoogle Scholar
• 25  Kawamura T, Suzuki J, Wang Y et al.: Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature460(7259),1140–1144 (2009).
  Medline CASGoogle Scholar
• 26  Li H, Collado M, Villasante A et al.: The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature460(7259),1136–1139 (2009).
  Medline CASGoogle Scholar
• 27  Marión R, Strati K, Li H et al.: A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature460(7259),1149–1153 (2009).
  Medline CASGoogle Scholar
• 28  Utikal J, Polo J, Stadtfeld M et al.: Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature460(7259),1145–1148 (2009).
  Medline CASGoogle Scholar
• 29  Banito A, Rashid S, Acosta J et al.: Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev.23(18),2134–2139 (2009).
  Medline CASGoogle Scholar
• 30  Hanna J, Saha K, Pando B et al.: Direct cell reprogramming is a stochastic process amenable to acceleration. Nature462(7273),595–601 (2009).
  Medline CASGoogle Scholar
• 31  Bhatia M, Bonnet D, Kapp U, Wang J, Murdoch B, Dick J: Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex vivo culture. J. Exp. Med.186(4),619–624 (1997).
  Medline CASGoogle Scholar
• 32  Steen R, Tjønnfjord G, Egeland T: Comparison of the phenotype and clonogenicity of normal CD34⁺ cells from umbilical cord blood, granulocyte colony-stimulating factor-mobilized peripheral blood, and adult human bone marrow. J. Hematother.3(4),253–262 (1994).
  Medline CASGoogle Scholar
• 33  Traycoff C, Abboud M, Laver J et al.: Evaluation of the in vitro behavior of phenotypically defined populations of umbilical cord blood hematopoietic progenitor cells. Exp. Hematol.22(2),215–222 (1994).
  Medline CASGoogle Scholar
• 34  Murry C, Keller G: Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell132(4),661–680 (2008).
  Medline CASGoogle Scholar
• 35  Orkin S, Zon L: Hematopoiesis: an evolving paradigm for stem cell biology. Cell132(4),631–644 (2008).
  Medline CASGoogle Scholar
• 36  Qiu C, Hanson E, Olivier E et al.: Differentiation of human embryonic stem cells into hematopoietic cells by coculture with human fetal liver cells recapitulates the globin switch that occurs early in development. Exp. Hematol.33(12),1450–1458 (2005).
  Medline CASGoogle Scholar
• 37  Chang K, Nelson A, Cao H et al.: Definitive-like erythroid cells derived from human embryonic stem cells coexpress high levels of embryonic and fetal globins with little or no adult globin. Blood108(5),1515–1523 (2006).
  Medline CASGoogle Scholar
• 38  Olivier E, Qiu C, Velho M, Hirsch R, Bouhassira E: Large-scale production of embryonic red blood cells from human embryonic stem cells. Exp. Hematol.34(12),1635–1642 (2006).
  Medline CASGoogle Scholar
• 39  Lu S, Feng Q, Park J et al.: Biologic properties and enucleation of red blood cells from human embryonic stem cells. Blood112(12),4475–4484 (2008).
  Medline CASGoogle Scholar
• 40  Ma F, Ebihara Y, Umeda K et al.: Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis. Proc. Natl Acad. Sci. USA105(35),13087–13092 (2008).
  Medline CASGoogle Scholar
• 41  Qiu C, Olivier E, Velho M, Bouhassira E: Globin switches in yolk sac-like primitive and fetal-like definitive red blood cells produced from human embryonic stem cells. Blood111(4),2400–2408 (2008).
  Medline CASGoogle Scholar
• 42  Zhan X, Dravid G, Ye Z et al.: Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro. Lancet364(9429),163–171.
  MedlineGoogle Scholar
• 43  Karlsson K, Cowley S, Martinez F, Shaw M, Minger S, James W: Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3. Exp. Hematol.36(9),1167–1175 (2008).
  Medline CASGoogle Scholar
• 44  Takayama N, Nishikii H, Usui J et al.: Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood111(11),5298–5306 (2008).
  Medline CASGoogle Scholar
• 45  Woll P, Grzywacz B, Tian X et al.: Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. Blood113(24),6094–6101 (2009).
  Medline CASGoogle Scholar
• 46  Kaufman D: Toward clinical therapies utilizing hematopoietic cells derived from human pluripotent stem cells. Blood114,3513–3523 (2009).
  Medline CASGoogle Scholar
• 47  Hanna J, Wernig M, Markoulaki S et al.: Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science318(5858),1920–1923 (2007).
  Medline CASGoogle Scholar
• 48  Kyba M, Perlingeiro R, Daley G: HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell109(1),29–37 (2002).
  Medline CASGoogle Scholar
• 49  Lengerke C, Grauer M, Niebuhr N et al.: Hematopoietic development from human induced pluripotent stem cells. Ann. NY Acad. Sci.1176,219–227 (2009).
  Medline CASGoogle Scholar
• 50  Grigoriadis A, Kennedy M, Bozec A et al.: Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood115(14),2769–2776 (2010).
  Medline CASGoogle Scholar
• 51  Choi K, Vodyanik M, Slukvin I: Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34⁺CD43⁺CD45⁺ progenitors. J. Clin. Invest.119(9),2818–2829 (2009).
  Medline CASGoogle Scholar
• 52  Choi K, Yu J, Smuga-Otto K et al.: Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells27(3),559–567 (2009).
  Medline CASGoogle Scholar
• 53  Chin M, Mason M, Xie W et al.: Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. Cell Stem Cell5(1),111–123 (2009).▪ One of the first gene expression profile studies comparing multiple lines of iPS cells to embryonic stem cells.
  Medline CASGoogle Scholar
• 54  Marchetto M, Yeo G, Kainohana O, Marsala M, Gage F, Muotri A: Transcriptional signature and memory retention of human-induced pluripotent stem cells. PLoS One4(9),e7076 (2009).
  MedlineGoogle Scholar
• 55  Doi A, Park I, Wen B et al.: Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet.41(12),1350–1353 (2009).
  Medline CASGoogle Scholar
• 56  Lister R, Pelizzola M, Dowen R et al.: Human DNA methylomes at base resolution show widespread epigenomic differences. Nature462(7271),315–322 (2009).
  Medline CASGoogle Scholar
• 57  Dimos J, Rodolfa K, Niakan K et al.: Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science321(5893),1218–1221 (2008).
  Medline CASGoogle Scholar
• 58  Park I, Arora N, Huo H et al.: Disease-specific induced pluripotent stem cells. Cell134(5),877–886 (2008).
  Medline CASGoogle Scholar
• 59  Ebert A, Yu J, Rose FJ et al.: Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature457(7227),277–280 (2009).
  Medline CASGoogle Scholar
• 60  Raya A, Rodríguez-Pizà I, Guenechea G et al.: Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature460(7251),53–59 (2009).
  Medline CASGoogle Scholar
• 61  Ye L, Chang J, Lin C, Sun X, Yu J, Kan Y: Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. Proc. Natl Acad. Sci. USA106(24),9826–9830 (2009).
  Medline CASGoogle Scholar
• 62  Wang Y, Jiang Y, Liu S, Sun X, Gao S: Generation of induced pluripotent stem cells from human β-thalassemia fibroblast cells. Cell Res.19(9),1120–1123 (2009).
  MedlineGoogle Scholar
• 63  Skoda R: The genetic basis of myeloproliferative disorders. Hematology Am. Soc. Hematol. Educ. Program1–10 (2007).
  MedlineGoogle Scholar
• 64  Levine R, Gilliland D: Myeloproliferative disorders. Blood112(6),2190–2198 (2008).
  Medline CASGoogle Scholar
• 65  Dameshek W: Some speculations on the myeloproliferative syndromes. Blood6(4),372–375 (1951).
  Medline CASGoogle Scholar
• 66  Baxter E, Scott L, Campbell P et al.: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet365(9464),1054–1061.
  MedlineGoogle Scholar
• 67  James C, Ugo V, Le Couédic J et al.: A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature434(7037),1144–1148 (2005).
  Medline CASGoogle Scholar
• 68  Kralovics R, Passamonti F, Buser A et al.: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med.352(17),1779–1790 (2005).
  Medline CASGoogle Scholar
• 69  Levine R, Wadleigh M, Cools J et al.: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell7(4),387–397 (2005).
  Medline CASGoogle Scholar
• 70  Zhao R, Xing S, Li Z et al.: Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem.280(24),22788–22792 (2005).
  Medline CASGoogle Scholar
• 71  Tefferi A, Lasho T, Gilliland G: JAK2 mutations in myeloproliferative disorders. N. Engl. J. Med.353(13),1416–1417; author reply 1416–1417 (2005).
  Medline CASGoogle Scholar
• 72  Moliterno A, Williams D, Rogers O, Spivak J: Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood108(12),3913–3915 (2006).
  Medline CASGoogle Scholar
• 73  Jones A, Kreil S, Zoi K et al.: Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood106(6),2162–2168 (2005).
  Medline CASGoogle Scholar
• 74  Dupont S, Massé A, James C et al.: The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood110(3),1013–1021 (2007).
  Medline CASGoogle Scholar
• 75  Scott L, Scott M, Campbell P, Green A: Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood108(7),2435–2437 (2006).
  Medline CASGoogle Scholar
• 76  Tiedt R, Hao-Shen H, Sobas M et al.: Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood111(8),3931–3940 (2008).
  Medline CASGoogle Scholar
• 77  Xing S, Wanting T, Zhao W et al.: Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood111(10),5109–5117 (2008).
  Medline CASGoogle Scholar
• 78  Kralovics R, Stockton D, Prchal J: Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood102(10),3793–3796 (2003).
  Medline CASGoogle Scholar
• 79  Bellanné-Chantelot C, Chaumarel I et al.: Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood108(1),346–352 (2006).
  Medline CASGoogle Scholar
• 80  Campbell P, Baxter E, Beer P et al.: Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood108(10),3548–3555 (2006).
  Medline CASGoogle Scholar
• 81  Kralovics R, Teo S, Li S et al.: Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood108(4),1377–1380 (2006).
  Medline CASGoogle Scholar
• 82  Levine R, Belisle C, Wadleigh M et al.: X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood107(10),4139–4141 (2006).
  Medline CASGoogle Scholar
• 83  Pardanani A, Fridley B, Lasho T, Gilliland D, Tefferi A: Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood111(5),2785–2789 (2008).
  Medline CASGoogle Scholar
• 84  Pietra D, Li S, Brisci A et al.: Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood111(3),1686–1689 (2008).
  Medline CASGoogle Scholar
• 85  Kiladjian J, Elkassar N, Cassinat B et al.: Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia20(6),1181–1183 (2006).
  Medline CASGoogle Scholar
• 86  Kilpivaara O, Mukherjee S, Schram A et al.: A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat. Genet.41(4),455–459 (2009).
  Medline CASGoogle Scholar
• 87  Olcaydu D, Harutyunyan A, Jäger R: A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat. Genet.41(4),450–454 (2009).
  Medline CASGoogle Scholar
• 88  Jones A, Chase A, Silver R et al.: JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat. Genet.41(4),446–449 (2009).
  Medline CASGoogle Scholar
• 89  Wernig G, Mercher T, Okabe R, Levine R, Lee B, Gilliland D: Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood107(11),4274–4281 (2006).
  Medline CASGoogle Scholar
• 90  Lacout C, Pisani D, Tulliez M, Gachelin F, Vainchenker W, Villeval J: JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood108(5),1652–1660 (2006).
  Medline CASGoogle Scholar
• 91  Zaleskas V, Krause D, Lazarides K et al.: Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One1,e18 (2006).
  MedlineGoogle Scholar
• 92  Zou J, Maeder M, Mali P et al.: Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell5(1),97–110 (2009).▪▪ The first report of gene targeting in human iPS cells.
  Medline CASGoogle Scholar
• 93  D’Andrea A, Grompe M: The Fanconi anaemia/BRCA pathway. Nat. Rev. Cancer3(1),23–34 (2003).
  MedlineGoogle Scholar
• 94  Tischkowitz M, Dokal I: Fanconi anaemia and leukaemia – clinical and molecular aspects. Br. J. Haematol.126(2),176–191 (2004).
  Medline CASGoogle Scholar
• 95  Parmar K, D’Andrea A, Niedernhofer L: Mouse models of Fanconi anemia. Mutat. Res.668(1–2),133–140 (2009).
  Medline CASGoogle Scholar
• 96  Tulpule A, Lensch M, Miller J et al.: Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. Blood115(17),3453–3462 (2010).
  Medline CASGoogle Scholar